HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ezetimibe + statin: insufficient benefit.

Abstract
After an acute coronary syndrome, the 6-year results of the "IMPROVE-IT" randomized trial showed a 1.6% reduction in the number of nonfatal myocardial infarctions with the ezetimibe + simvastatin combination compared with simvastatin alone, but no reduction in mortality.
Authors
JournalPrescrire international (Prescrire Int) Vol. 25 Issue 175 Pg. 245-246 (Oct 2016) ISSN: 1167-7422 [Print] France
PMID30645833 (Publication Type: Journal Article)
Chemical References
  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • Ezetimibe, Simvastatin Drug Combination
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Topics
  • Acute Coronary Syndrome (blood, diagnosis, drug therapy, mortality)
  • Anticholesteremic Agents (adverse effects, therapeutic use)
  • Biomarkers (blood)
  • Cholesterol, LDL (blood)
  • Dyslipidemias (blood, diagnosis, drug therapy, mortality)
  • Ezetimibe, Simvastatin Drug Combination (adverse effects, therapeutic use)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: